JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout

Rizwan Siddiqui

Tue, February 24, 2026 at 3:23 PM GMT+9 2 min read

In this article:

RVMD

+1.83%

JPM

-4.22%

Revolution Medicines Inc. (NASDAQ:RVMD) is among the 15 Undervalued Momentum Stocks That Are Taking Off.

JPMorgan added Overweight-rated Revolution Medicines Inc. (NASDAQ:RVMD) to its “Positive Catalyst Watch” list as per a February 17 report. The development came ahead of the RASolute 302 second-line pancreatic ductal adenocarcinoma readout expected in H1 2026.

According to the report, JPMorgan is confident in Daraxonrasib, citing encouraging performance trends for the drug relative to the historical chemotherapy benchmark. The firm sees a positive outcome as median overall survival in the 9–10 months range, alongside a hazard ratio in the mid-0.6-low-0.7 range.

Before this update, early in the first week of February, JPMorgan analyst Brian Cheng had raised his price target on Revolution Medicines Inc. (NASDAQ:RVMD) by around 33% to $122 (from $92), citing updates to the company’s financial model. The firm maintained an Overweight rating.

Earlier, at the end of January, Oppenheimer analyst Jay Olson doubled his price target on the stock from $75 to $150, as the firm believes that Revolution Medicines Inc. (NASDAQ:RVMD) could be an attractive acquisition candidate in 2026, particularly as the company is expected to see multiple milestones this year.

Revolution Medicines shares have performed well, with over 140% returns in the past year and gains of 28% in 2026 as of February 20. However, the stock currently trades 18% below its 52-week high of $124.5.

Revolution Medicines Inc. (NASDAQ:RVMD) is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. It has several RAS(ON) inhibitors currently in clinical development, including daraxonrasib (RMC-6236).

While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Software Infrastructure Stocks to Buy According to Hedge Funds and Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy.

Disclosure: None. This article is originally published at Insider Monkey.

Terms and Privacy Policy

Privacy Dashboard

More Info